Supplementary Tables from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

These four supplementary tables summarize the following: Supplementary Table 1. TTI-621 binding to human tumor cell lines Supplementary Table 2. TTI-621 binding to human primary tumor samples Supplementary Table 3. TTI-621 binding to peripheral blood cells of healthy donors Supplementary Table 4: TTI-621 Potency In Vitro